Therapeutic efficacy of the combination of CX-4945 and WDR5 inhibitor in patient-derived T-ALL leukemia-xenograft (PDX) mouse model. (A) Comparison of Kaplan-Meier survival curves in the combination of CX-4945 and WDR5 inhibitor OICR-9429 compared with either single drug controls in 3 different PDX mouse models: PDX-P1 (Patient, [Pt.] T-ALL-P1 in supplemental Table 3), PDX-P2 (Pt. T-ALL-P2), and PDX-P3 (Pt. T-ALL-P3). (B) Comparison of percentage of human CD45⁺CD7⁺ cells in the spleen of the mice in combo group vs either single drug controls. (C-E) Comparison of mRNA level of WDR5, ATAD2, CCNE2, and CDK2 in combo group vs either single drug controls in the spleen of the mouse models. The mice in panels A-E were treated with the indicated drugs for 25 days, and then, when the vehicle mice met the early removal criteria due to the excessive leukemia burden, the mice were euthanized and the single cells were isolated from the spleen for flow cytometry analysis; the mRNA of the cells was prepared for qPCR analysis. ∗∗∗P < .001. OI, OICR-9429.